Metformin confers an edge in survival

IN A retrospective, observational study in 90,000 people with diabetes and matched controls, researchers showed that, when compared to those treated with metformin, all-cause mortality survival time was 15% lower in individuals without diabetes over five years of follow-up.

Participants with diabetes treated with sulphonylureas had a 38% lower survival time compared with those treated with metformin monotherapy.

Survival was marginally better with metformin compared to untreated controls even in people who had not received antiplatelets, lipid-lowering and antihypertensive medications at baseline, the study showed.